title: The new insight of prostate-specific antigen reduction during finasteride therapy in aging men.
abstract: OBJECTIVE
  To evaluate the effect of finasteride on prostate-specific antigen (PSA) in Chinese population.
  
  
  METHODS
  From Feb 2011 to Jan 2012, 83 benign prostatic hyperplasia (BPH) patients with prostate volume (PV) >30 mL were enrolled in our study. All the patients were older than 50 years and all of them received combined therapy (finasteride + doxazosin). All the patients were required for 1-year follow-up. PSA level and PV was measured at the start, 6 and 12 months, respectively.
  
  
  RESULTS
  79 patients completed the follow up. PSA level reduced by approximately 40 % during finasteride therapy. We defined baseline PSA as PSA1, PSA at 6 months as PSA2, PSA at 12 months as PSA3. PSA1 was significantly correlated with PSA2/PSA1 and PSA3/PSA1. However, prostate volume was not correlated with PSA1. We divided the patients into three groups according to PSA level. Groups 1, 2, 3 represented the patients with PSA less than 2 ng/mL, between 2 and 4 ng/mL and greater than 4 ng/mL, respectively. Both the PSA2/PSA1 and the PSA3/PSA1 had significant difference among three groups. Furthermore, group 1 and group 2 both showed the fairly large data variance.
  
  
  CONCLUSIONS
  When baseline PSA level was greater than 4 ng/mL, the doubling rule could be used for screening. When baseline PSA level was less than 4 ng/Ml, the doubling rule might not be an accurate predictor. We can use the PSA rise from nadir or proPSA to predict prostate cancer.
authors.affiliation: Department of Urology, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China.
authors.forename: Ding
authors.initials: D
authors.lastname: Xu
authors.affiliation: Department of Urology, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ding
authors.affiliation: Department of Ultrasound, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors.forename: Yunkai
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Urology, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China.
authors.forename: Xiaoqiang
authors.initials: X
authors.lastname: Qian
authors.affiliation: Department of Urology, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China.
authors.forename: Liujian
authors.initials: L
authors.lastname: Duan
authors.affiliation: Department of Urology, XinHua Hospital Affiliate to Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Rd, Shanghai, 200092, China. listerdingzai@sohu.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Qi
mesh_terms: D000368:Aged; D044466:Asian People; D017292:Doxazosin / Q000008:administration & dosage; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000473:pathology
chemical_list: D018120:Finasteride; D017430:Prostate-Specific Antigen; D017292:Doxazosin
keywords: Benign prostatic hyperplasia; Finasteride; Prostate-specific antigen